Status:

COMPLETED

Low-Calorie Diet in People With Prediabetes/Metabolic Syndrome

Lead Sponsor:

University of Liverpool

Collaborating Sponsors:

University of Surrey

Perspectum

Conditions:

Obesity

NAFLD

Eligibility:

All Genders

18-55 years

Phase:

NA

Brief Summary

Significant weight reduction, achieved by low-calorie diet (LCD), will mobilise ectopic fat (visceral and particularly liver fat), improving insulin sensitivity and other metabolic syndrome components...

Detailed Description

Prediabetes affects up to 35% of the population. It is defined as an intermediate metabolic state of glucose dysregulation between normoglycaemia and type 2 diabetes (T2D). Prediabetic individuals hav...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • The investigators shall recruit participants with the following characteristics:
  • Men and women
  • aged 18-55 years\*,
  • BMI 30-40 kg/m2 , BMI\>27 kg/m2 for Chinese/South Asians
  • Any one of the following three metabolic criteria:
  • a diagnosis of prediabetes (HbA1c 42-47 mmol/mol), OR
  • NAFLD (based on fatty liver index, FLI \>60). FLI will be determined using waist circumference, BMI, serum triglyceride and GGT (gamma-glutamyltransferase). OR
  • a diagnosis of metabolic syndrome using the IDF metabolic syndrome criteria (see below,
  • Exclusion criteria:
  • Individuals with normal glucose tolerance (NGT) or type 1 or type 2 diabetes (T2D).
  • Anyone engaged in active weight loss (\>5kg weight loss in the last 6 months), currently engaged with weight management service, previous bariatric surgery, on weight-lowering medications (e.g. orlistat or liraglutide) or with a history of an eating disorder.
  • planning pregnancy/6 months post-partum,
  • known structural cardiac disease or anyone with major atherosclerotic disease
  • history of stroke within the last 3 months
  • Active mental health illness (e.g. severe depression, bipolar disorder, schizophrenia or other psychotic disorders). Use of drug with known major effects on bodyweight (e.g. corticosteroid, anti-psychotic, anticonvulsants etc).
  • Planning pregnancy within the next 6 months and until \>6 months post-partum or breastfeeding
  • Substance abuse e.g. drugs/alcohol.
  • Eating disorder, previous bariatric surgery, currently taking weight loss drugs or already engaged with weight management service
  • Learning difficulties
  • A contraindication to magnetic resonance scanning will exclude the patient from the MRI component of the study

Exclusion

    Key Trial Info

    Start Date :

    June 1 2021

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 31 2024

    Estimated Enrollment :

    44 Patients enrolled

    Trial Details

    Trial ID

    NCT04786418

    Start Date

    June 1 2021

    End Date

    December 31 2024

    Last Update

    June 27 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Liverpool University Hospital NHS Foundation Trust are an NHS organisation

    Liverpool, United Kingdom, L97AL